System and Method for Decision Support Guiding Diabetes Treatment From Live Glucose Data

This patent describes a system that uses a person’s glucose readings to work out timely guidance for managing diabetes, helping the patient or caregiver decide what to do next. It comes from Dexcom, Inc., a leading maker of continuous glucose monitoring systems.

The Problem

Managing diabetes means making frequent decisions, when to eat, exercise, or take insulin, and getting those decisions wrong can lead to dangerously high blood sugar (hyperglycemia) or dangerously low blood sugar (hypoglycemia), which in severe cases can cause seizures or worse. Continuous glucose monitors provide a steady stream of readings, but a number on a screen does not tell a person what action to take or when. The harder task is to translate live glucose data into specific, well-timed guidance that fits the individual’s situation, so the user is not left to interpret the raw values alone. A system that could determine both what guidance to give and the right moment to give it would make day-to-day management safer and less stressful.

What This Invention Does

The patent provides systems and methods that deliver decision-support guidance for a physiologic condition such as diabetes, based on a patient’s glucose concentration level. The glucose level is fed into a stored model that determines a state, and the guidance is then worked out based at least in part on that determined state. The system also addresses timing, determining when to deliver or when to compute the guidance for a patient or caregiver, so support arrives when it is useful rather than as a constant stream. By combining a model of the patient’s state with the live reading, the approach turns continuous glucose data into specific guidance about managing the condition. The filing covers both the system and the methods of using analyte sensor data to support treatment decisions.

Key Features

• Model-based state. A stored model converts a glucose reading into a determined state for the patient.
• Tailored guidance. Decision-support guidance is generated based at least in part on that state.
• Timing logic. The system determines when to deliver or compute guidance so it is timely.
• Patient or caregiver. Support can be directed to the person with diabetes or to a caregiver.
• Sensor-driven. The approach works from the live data of an analyte sensor such as a glucose monitor.

Who Is Behind It

The applicant is Dexcom, Inc., a company based in San Diego, California, that develops continuous glucose monitoring systems and related software used by people with diabetes around the world. The filing names a large group of inventors from the company’s engineering and clinical teams. This filing is a divisional application from an earlier related Australian application.

Why It Matters

The value of continuous glucose data is fully realised only when it helps people make better choices at the right moments. A decision-support system that reads a patient’s state and offers well-timed guidance can reduce the burden of constant self-management and help avoid dangerous highs and lows. Protecting the system and methods in Australia supports the company’s products and commercial activity in the local market.

Related Concepts

• Continuous glucose monitor – the source of the live data the system uses.
• Diabetes – the condition the guidance helps manage.
• Hypoglycemia – the dangerous low-glucose state the system helps avoid.
• Hyperglycemia – the dangerous high-glucose state the system helps avoid.
• Clinical decision support system – the broader category of tools that guide medical decisions.

---

AU 2026201971 was published in the Australian Official Journal of Patents on 2 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.